Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S : announces a new hospital as a clinical routine customer in Greece

10/25/2021 | 11:44pm EST

COMPANY ANNOUNCEMENT Inside Information - No. 19, 2021 - 26 October 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces the first order from a new clinical routine customer in Greece.

The customer is a hospital located in the Athens area. The hospital is a public hospital with more than 700 beds and is one of Greece's leading university hospitals. The hospital has placed the first order of suPARnostic® TurbiLatex for its Roche cobas 701 system.  The hospital has previously also been a participant in the SAVE-MORE COVID-19 study using the suPARnostic® Quick Triage product.

ViroGates has revamped its disclosure policy to introduce stricter criteria for announcing clinical routine customers.  ViroGates will announce a clinical customer once the customer has either 1) placed the second purchase order for clinical use or 2) placed the first purchase order with a clear intention of placing future orders for clinical use.  If a customer has not placed a clinical order in the previous twelve months, ViroGates will consider the customer churned. To ensure transparency, ViroGates will include information about the number of clinical routine customers in all future financial reports (interim, half-year and annual reports) based on the definition above.

Jakob Knudsen, Chief Executive Officer of ViroGates, said:”We are happy to add another clinical customer in Greece. We have worked with the customer on various projects and are excited to learn that this has turned into clinical use. Greece has adopted suPARnostic® TurbiLatex very well, and we are happy to see that the product is used in general acute care triage decisions.”

The announcement can be found at: https://www.virogates.com/investor/announcements

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 750 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

  • Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

© Ritzau Denmark, source Ritzau English Regulatory Releases

All news about VIROGATES A/S
12/03FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
12/01ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
11/29NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
11/11Interim Report – Q1-Q3, 2021
PU
11/11VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
11/11ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/11ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
11/11ViroGates A/S Announces Delay in the Development of suPARnostic? POC+
CI
11/10Invitation to ViroGates' Q3 2021 presentation
AQ
11/05Elevated preoperative suPAR is a strong and independent risk marker for postoperative c..
PU
More news
Financials
Sales 2020 5,35 M 0,81 M 0,81 M
Net income 2020 -18,7 M -2,85 M -2,85 M
Net cash 2020 33,5 M 5,10 M 5,10 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 466 M 70,7 M 70,9 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float 47,9%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S81.60%71
EXACT SCIENCES CORPORATION-39.19%13 198
GUARDANT HEALTH, INC.-24.22%9 220
BGI GENOMICS CO., LTD.-28.68%5 894
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.64%3 579
INVITAE CORPORATION-64.15%3 393